Zhejiang Qizheng Pharmaceutical Co., Ltd

Dapagliflozin tablets (specification: 10 mg) developed by Zhejiang Qizheng Pharmaceutical Co., Ltd. were used as the test preparation, and dapagliflozin tablets (specification: 10 mg, trade name: Andatang®) originally developed by AstraZeneca AB were used as the reference preparation. The bioequivalence and safety of the test preparation and the reference preparation were evaluated in healthy subjects under the fasting state.

Palbociclib Tablets (Specification: 125 mg) produced and provided by Zhejiang Qizheng Pharmaceutical Co., Ltd. was used as the test preparation, and Palbociclib Tablets (Specification: 125 mg, Trade Name: IBRANCE®) produced by Pfizer Manufacturing Deutschland GmbH and certified by Pfizer Europe MA EEIG was used as the reference preparation. The bioequivalence of the test preparation and the reference preparation in healthy subjects was evaluated under fasting, postprandial and fasting (antacid conditions) conditions.

Primary objective: To evaluate the bioequivalence of the test and reference preparations in healthy subjects under fasting and fed conditions, using lenvatinib mesylate capsules (specification: 4 mg) provided by Zhejiang Qizheng Pharmaceutical Co., Ltd. as the test preparation and lenvatinib mesylate capsules (specification: 4 mg, trade name: LENVIMA ®) certified by the original Eisai Europe Limited as the reference preparation. Secondary objective: To observe the safety of the test and reference preparations in healthy subjects under fasting and fed conditions.